u/PerspectivePuzzled59

Hi everybody,

Saw VMAR dropped their shareholder update yesterday and it actually looks pretty decent, so figured I’d share. I only have a tiny position, mostly researching for fun, but the direction they’re heading feels promising.

Quick rundown:

They specialize in high-voltage electric boat motors (E-Motion) and sell both electric and traditional boats through Nautical Ventures, the dealership chain they acquired last year in Florida. Nice vertical integration with their own retail and service network.

What stood out in the latest update (H1 FY2026):

• Electric boat contracts up over 400% YoY, actual signed deals.
• Nautical Ventures cleaned house: inventory -37%, floor plan financing -57% ->> operations and cash flow looking a lot healthier.
• Retail side is getting very close to EBITDA breakeven in under a year.
• Planning to sell a Fort Lauderdale property for ~$5M non-dilutive cash.
• New SPECTR 26 electric pontoon launch + fresh partnerships (Twin Vee, etc.).
• Just dual-listed on TSX Venture.

Cash position around $4.1M, working capital ~$10M. Market cap is still super small (~$1.3-1.5M), so typical penny stock volatility.

Risks:

• Still unprofitable with ugly EPS.
• Electric marine market is early-stage and competitive.
• Dilution risk remains (ATM facility).

Overall, it feels like they’re making a solid shift from pure R&D to actual commercial execution. If the electric boating trend keeps building (especially with green incentives), having the retail network could give them a meaningful edge. Not saying it’s a moonshot, but worth keeping an eye on.

Anyone else following this one?

"The FDA’s answer always seems to be the same when it comes to rare disease treatments: Wait, wait, and then wait some more."

"DMD killed my beloved brothers Angelo and Antonio in their early 20s. It is a fatal genetic condition that progressively destroys muscles throughout the body. My son now faces my brothers’ fate.

In the 1990s, Angelo agreed to experimental spinal surgery to treat his DMD. Although he knew chances of survival were slim, he allowed doctors to put a metal rod in his spine, and thankfully, he lived several more years. Angelo did not hesitate, as he felt the treatment would help researchers understand more about this vicious disease.

That choice was his alone. No agency in far-off Washington, D.C., blocked him from taking his leap of faith and contributing to a possible cure.

Unlike when my brothers were alive, there are now therapies that can slow the progression of Duchenne and extend lives. Many patients are living higher-quality lives because of these advances.

Last summer, our family was looking into enrolling Ryu in a program for a DMD treatment called Elevidys. Today, we cannot even consider this treatment that could preserve Ryu’s muscle function, because the FDA has effectively made that decision for us by restricting treatment to ambulatory patients. They blocked the only gene therapy treatment for children who, like Ryu, are already in a wheelchair. "

President Trump has been clear about his goals to unleash the greatness of American industry, create life-saving medicines at a rapid pace, and empower Americans to make their own health choices. While former FDA Commissioner Marty Makary was misaligned, the Trump administration should ensure the next person to take the role is focused on this vision for America.

Makary spent years rightly criticizing the medical establishment's COVID-era failures and promised to cut through FDA bureaucracy to get life-saving drugs to patients faster. Instead, the FDA only approved 46 drugs in 2025, lower than every year in the last decade except 2022.

The Commissioner also reversed previous FDA guidance, pulling the rug out from under American companies seeking to treat rare diseases like erythropoietic protoporphyria, Hunter syndrome, and Sanfilippo syndrome. In one case, the FDA told gene therapy company uniQure it "no longer agrees" that a previously approved study plan would support approval of a Huntington's disease treatment.

Amidst the regulatory chaos, the FDA had also been missing its review deadlines for drugs. Last summer, the agency got a lot of attention when it failed to meet its deadline, delaying KalVista's oral treatment option, Ekterly, for acute attacks of hereditary angioedema (HAE).

There have been quantifiable consequences of this regulatory uncertainty. Shares of biotech firms have declined sharply due to investor concerns. Biotech companies had 190 layoff rounds by the end of Q3 2025 and130 biopharmaceutical companies have cut 13,470 jobs. Capital flowing into U.S. biotech companies was down 57% year-over-year, and by the middle of last year only seven biotech companies had managed to go public year-to-date (compared to the 30 - 40 IPOs that would signal a healthy sector).

"Last month, I invited Makary to my home to see firsthand what life is like for a child whose muscles are slowly wasting away. I now extend that invitation to acting FDA Commissioner Kyle Diamantas, and whomever the president permanently appoints to lead the agency.

As Ryu told me recently as he was using a machine to help him cough up mucus his lungs are too weak to handle, “Mom, this sucks. But you telling my story makes this a lot easier.”

The next FDA leaders have power over the life of my son. That’s why we wanted to come to Washington—to put a face to FDA treatment delays.

We are seeking partners from inside the halls of government—or as Ryu would call them, “heroes.”

It is up to the president and the U.S. Senate to ensure the next FDA appointee finally puts patients first. "

Nvidia just crossed $5.5 trillion market cap after news that CEO Jensen Huang is flying with Trump to meet Xi Jinping.

Allowing controlled exports of advanced chips to China is smart economics:

• China was a massive market. Selling chips brings billions back to American companies and shareholders.
• US collects 25% tariffs -> money straight into American coffers.
• Maintains US tech dominance. If we don’t sell, China will just build faster and catch up.
• Protects thousands of high-paying US jobs in chip design and innovation.

Previous export bans already cost Nvidia ~$8-15B in revenue.

Smart, controlled sales = America wins both economically and strategically.

Disclaimer: This is for informational purposes only and is not financial advice. Biotech investing carries substantial risk of loss. Please do your own research.

Tonix has successfully made the difficult transition from a pure R&D biotech to a commercial-stage company. Its lead product TONMYA received FDA approval in August 2025 as the first new fibromyalgia treatment in over 15 years. The drug launched in November 2025 and has shown encouraging early momentum, with thousands of patients starting therapy in Q1 2026.

A major catalyst arrived in May 2026 with broad payer coverage covering tens of millions of lives. The company currently holds approximately $185 million in cash, providing a runway into Q2 2027, while 2026 revenue is projected to grow over 140% year-over-year.

Beyond TONMYA, the pipeline adds further optionality with potential label expansions into major depressive disorder and acute stress disorder (data expected in the second half of 2026), along with a Lyme disease prevention program advancing toward Phase 2.

At a market cap around $200 million, Tonix appears to be at a classic inflection point. If TONMYA execution continues positively, the company could see meaningful re-rating over the next 12-18 months.

That said, risks remain typical for biotech: slower-than-expected adoption, cash burn, potential dilution, and high volatility.

A high-risk, high-reward story centered on TONMYA’s commercial ramp in 2026–2027. Definitely one to keep on the radar.

Did a pretty deep dive recently into some of the newer psychedelic biotech approaches and I keep coming back to the same question: how are these treatments actually supposed to scale in the real world? A lot of the attention goes to efficacy headlines, but some of the treatment models honestly sound difficult operationally. Long monitored sessions, clinic time, staffing requirements etc. Even if the science works, the logistics side still matters.

What caught my attention with one company I was reading about is that they’re trying to shorten and stabilize the experience itself instead of just building therapy infrastructure around long sessions. The idea is basically that shorter and more predictable treatment windows could make these therapies easier to integrate into existing healthcare systems if they ever become mainstream.

Still very high risk obviously. CNS biotech destroys people financially every year and the psychedelic space is crowded now. But after reading through a bunch of companies in the sector, this approach at least felt like it was trying to solve a practical healthcare delivery problem rather than just chasing hype headlines.

Curious if anyone else here has looked into the “short-duration” side of the space because I honestly think it might end up mattering more than people expect.

Update: the company was Cybin (HELP). Their whole angle around shorter and more predictable sessions honestly feels more practical than some of the longer clinic heavy models I’ve been reading about.

"At 1:30pm today, FDA Commissioner DrMakaryFDA will unveil FDA's real-time clinical trials initiative, a major step to accelerate cures for patients."

If Real time clinical trials can actually speed up development and approval for rare diseases, this could be game changing! Just hope it moves fast, our kids don’t have years to wait. Let’s get it done. Boys with DMD have been waiting far too long, Elevidys is already approved but many are still struggling to get access. Hope this initiative delivers real change

Dear DMD families,

Good news to share: Sarepta is now pursuing traditional (full) FDA approval for AMONDYS 45 and VYONDYS 53.

This move strengthens the future of these important treatments for our boys with exon 45 and 53.

Let’s keep the hope and strength together.